Health Economics›Non-Hodgkin lymphoma pediatric›Untreated induction

Untreated induction

Non-Hodgkin lymphoma pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
R-COPADM Variant #01 Partial	—	R 53 356	21d	—	—	2	R 106 712 PFS proxy	1
COPADM Variant #01 Partial	—	R 1 546	—	—	—	~2	~R 3 093 indirect	—

2 of 2 regimens shown